ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.17) by 10.26 percent.
ITeos Therapeutics Q3 2024 GAAP EPS $(1.05) Beats $(1.17) Estimate, Pro Forma Cash And Investment Balance Of $683.9M As Of September 30, 2024 Expected To Provide Runway Through 2027 Across A Number Of Impactful Portfolio Milestones
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated